Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Phase II Study of NRX 195183 Induction and NRX 195183 Combined With Arsenic Trioxide (As2o3) as Initial Consolidation Therapy Followed by Continuous NRX 195183 Maintenance Therapy for Patients With Untreated Acute Promyelocytic Leukemia
Status: Enrolling
Updated:  10/24/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Phase II Study of NRX 195183 Induction and NRX 195183 Combined With Arsenic Trioxide (As2o3) as Initial Consolidation Therapy Followed by Continuous NRX 195183 Maintenance Therapy for Patients With Untreated Acute Promyelocytic Leukemia
Status: Enrolling
Updated: 10/24/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma
Status: Enrolling
Updated:  10/27/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
A Phase 1 Trial of the Combination of Everolimus (RAD001) and Bortezomib (VELCADE) for Relapsed or Refractory Lymphoma
Status: Enrolling
Updated: 10/27/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
City of Hope National Medical Center
mi
from
Duarte, CA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
City of Hope
mi
from
Duarte, CA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Rocky Mountain Cancer Center
mi
from
Denver, CO
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Rocky Mountain Cancer Center
mi
from
Denver, CO
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Georgetown University Medical Center
mi
from
Washington,
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Georgetown University Hospital
mi
from
Washington,
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Lombardi Cancer Center
mi
from
Washington,
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Lombardi Cancer Center
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
The George Washington University Medical Faculty Associates (Gwmfa)
mi
from
Washington,
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
The George Washington University Medical Faculty Associates (Gwmfa)
mi
from
Washington,
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
The Emory Clinic
mi
from
Atlanta, GA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
The Emory Clinic
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Emory University Hospital
mi
from
Atlanta, GA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Emory University Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Investigational Drug Service (Drug Ship)
mi
from
Atlanta, GA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Investigational Drug Service (Drug Ship)
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Winship Cancer Institute
mi
from
Atlanta, GA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Oncology Specialists, S.C.
mi
from
Niles, IL
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Oncology Specialists, S.C.
mi
from
Niles, IL
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Franciscan St. Francis Health, Site
mi
from
Indianapolis, IN
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Franciscan St. Francis Health, Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Indiana Blood and Marrow Transplantation Research-Franciscan St Francis Health Center Inc.
mi
from
Indianapolis, IN
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Indiana Blood and Marrow Transplantation Research-Franciscan St Francis Health Center Inc.
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Indiana Blood and Marrow Transplantation Research
mi
from
Indianapolis, IN
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Indiana Blood and Marrow Transplantation Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
LSU Health Sciences Center
mi
from
Shreveport, LA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
LSU Health Sciences Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Louisiana State University Health Sciences Center, Feist-Weiller Cancer Center
mi
from
Shreveport, LA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Louisiana State University Health Sciences Center, Feist-Weiller Cancer Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
University of Maryland Medical Center
mi
from
Baltimore, MD
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
University of Maryland Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
University of Maryland
mi
from
Baltimore, MD
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Hudson Valley Hematology and Oncology Associates
mi
from
Hawthorne, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Hudson Valley Hematology and Oncology Associates
mi
from
Hawthorne, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Westchester Oncology Hematology Group, P.C.
mi
from
Hawthorne, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Westchester Oncology Hematology Group, P.C.
mi
from
Hawthorne, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
New York Presbyterian Hospital (Cornell)
mi
from
New York, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
New York Presbyterian Hospital (Cornell)
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
New York-Presbyterian Hospital
mi
from
New York, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
New York-Presbyterian Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Weill Cornell Medical Center
mi
from
New York, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Weill-Cornell Medical College
mi
from
New York, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
University of Rochester Cancer Center Pharmacy
mi
from
Rochester, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
University of Rochester Cancer Center Pharmacy
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center
mi
from
Rochester, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
University of Rochester Medical Center Strong Memorial Hospital - James P. Wilmot Cancer Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Westchester Medical Center
mi
from
Valhalla, NY
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Westchester Medical Center
mi
from
Valhalla, NY
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
The University Of Texas
mi
from
Houston, TX
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
The University Of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated:  10/27/2015
Hospital Universitario Austral
mi
from
Derqui-Pilar,
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
A Phase 1/2 Study Of Bosutinib (SKI-606) In Philadelphia Chromosome Positive Leukemias
Status: Enrolling
Updated: 10/27/2015
Hospital Universitario Austral
mi
from
Derqui-Pilar,
Click here to add this to my saved trials
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Status: Enrolling
Updated:  10/27/2015
University of Arizona Cancer Center
mi
from
Tucson, AZ
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Status: Enrolling
Updated: 10/27/2015
University of Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Status: Enrolling
Updated:  10/27/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Status: Enrolling
Updated: 10/27/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Status: Enrolling
Updated:  10/27/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
A Clinical Trial of Decitabine in Patients With Myelodysplastic Syndrome
Phase I/II Trial of Subcutaneous Decitabine Maximizing Genomic Demethylation in Patients With Myelodysplastic Syndrome.
Status: Enrolling
Updated: 10/27/2015
Albert Einstein College of Medicine
mi
from
Bronx, NY
Click here to add this to my saved trials
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Status: Enrolling
Updated:  10/28/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
Status: Enrolling
Updated: 10/28/2015
Huntsman Cancer Institute
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Therapeutic Research Institute of Orange County
mi
from
Laguna Hills, CA
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Therapeutic Research Institute of Orange County
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Rocky Mountain Blood and Marrow Transplant Program
mi
from
Denver, CO
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Rocky Mountain Blood and Marrow Transplant Program
mi
from
Denver, CO
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Oncology & Hematology Assoc. of W. Broward
mi
from
Tamarac, FL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Oncology & Hematology Assoc. of W. Broward
mi
from
Tamarac, FL
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Northwestern University
mi
from
Chicago, IL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  10/28/2015
Orchard Research
mi
from
Skokie, IL
Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma
An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 10/28/2015
Orchard Research
mi
from
Skokie, IL
Click here to add this to my saved trials